A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depressive Disorder Who Experience a Loss of Interest and Pleasure
- Conditions
- Depressive Disorder, MajorAnhedonia
- Interventions
- Other: Placebo
- First Posted Date
- 2024-10-10
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 660
- Registration Number
- NCT06635135
- Locations
- π§πͺ
Vitaz, Sint Niklaas, Belgium
π§π·CAEP Centro Avancado De Estudos E Pesquisas, Campinas, Brazil
π§π·Centro Integrado Facili, Sao Bernardo do Campo, Brazil
A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
- Conditions
- Leukemia, Myeloid, AcuteMyelodysplastic Neoplasms
- Interventions
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 100
- Registration Number
- NCT06618001
- Locations
- π¬π§
The Christie NHS Foundation Trust Christie Hospital, Manchester, United Kingdom
π¨π¦Vancouver General Hospital, Vancouver, British Columbia, Canada
π¨π¦Princess Margaret Hospital, Toronto, Ontario, Canada
A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 80
- Registration Number
- NCT06604715
- Locations
- πͺπΈ
Hosp. Univ. Germans Trias I Pujol, Badalona, Spain
πͺπΈHosp Clinic de Barcelona, Barcelona, Spain
πͺπΈHosp Clinico Univ de Salamanca, Salamanca, Spain
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT06577025
- Locations
- π§π·
Instituto D Or de Pesquisa e Ensino, Salvador, Brazil
π©πͺUniversitaetsklinikum Tuebingen, Tuebingen, Germany
π©πͺUniversitatsklinikum Wurzburg, Wuerzburg, Germany
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
- Conditions
- Depressive Disorder, Major
- Interventions
- Drug: PlaceboDrug: Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 752
- Registration Number
- NCT06559306
- Locations
- π§π¬
DCC 'Sv. Vrach and Sv. Sv. Kuzma and Damyan', OOD, Sofia, Bulgaria
π§π¬Medical Center ZaraMed, Stara Zagora, Bulgaria
πΊπΈUniversity of Alabama at Birmingham, Birmingham, Alabama, United States
A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2024-08-13
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 10
- Registration Number
- NCT06550895
- Locations
- πΊπΈ
University of Pennsylvania, Philadelphia, Pennsylvania, United States
πΊπΈUniversity of Iowa Hospital and Clinics, Iowa City, Iowa, United States
πΊπΈNorton Cancer Institute, Louisville, Kentucky, United States
A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 12
- Registration Number
- NCT06532032
- Locations
- πΉπ·
Ankara Bilkent Sehir Hastanesi, Cankaya, Turkey
πΊπΈOncology Hematology Associates, Springfield, Missouri, United States
πΊπΈHunterdon Hematology Oncology, Flemington, New Jersey, United States
A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
- Conditions
- Thrombocytopenia, Neonatal Alloimmune
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 50
- Registration Number
- NCT06533098
- Locations
- π©πͺ
Universitaetsklinikum Tuebingen, Tuebingen, Germany
π¬π§John Radcliffe Hospital, Oxford, United Kingdom
π¦πΉMedizinische Universitaet Graz, Graz, Austria
A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant
- Conditions
- AnhedoniaDepressive Disorder, Major
- Interventions
- Other: Placebo
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 101
- Registration Number
- NCT06514742
- Locations
- ππΊ
Bugat Pal Korhaz, Gyongyos, Hungary
πΊπΈUAB Huntsville Regional Medical Campus, Huntsville, Alabama, United States
πΊπΈIMA Clinical Research PC, Phoenix, Arizona, United States
A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity
- Conditions
- Relapse Multiple MyelomaRefractory Multiple Myeloma
- Interventions
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 130
- Registration Number
- NCT06500884
- Locations
- πΊπΈ
Duke University Medical Center, Durham, North Carolina, United States
πΊπΈVirginia Commonwealth University - Massey Cancer Center, Richmond, Virginia, United States
πͺπΈHosp. Univ. 12 de Octubre, Madrid, Spain